Alice in Wonderland may come to mind as you read this issue of LEAP, because we are moving from the large to the small, and back again: A rheumatic disease is big, and its effect can be devastating. However, a disease such as rheumatoid arthritis, scleroderma, or Sjögren’s is, in fact, multiple diseases, each slightly different.
The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 […]
For too long, doctors treating rheumatic diseases have had to base their management on instinct and experience.
The problem is that each physician has a limited experience – which means that many times we basically had to guess at how to treat a specific patient, using trial and error to find out what might work best.
In this issue of LEAP you can read about our precision approach to an increasingly common illness, gout, to a rare illness linked to Sjögren’s, and to cancer patients who are developing some autoimmune-mediated complications. And we are especially excited to share with you a tremendous breakthrough in understanding how rheumatoid arthritis begins.
You may notice a theme to this issue of LEAP: change. Our cover story features research in Sjögren’s that has the potential to transform the way drugs are tested in clinical trials, to […]
This issue of Leap, although autoimmunity is on the cover, is actually about the many points of connection here in the Division of Rheumatology. First, of course, is our connection to our patients. It’s not just physicians, nurses, and staff. It’s also our scientists, working to discover how these diseases start and how they might be stopped.
